Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetic Profile of Vincristine Administered With Imatinib for Bcr-Abl Positive Acute Lymphoblastic Leukemia (ALL) Compared to That Without Imatinib for Bcr-Abl Negative ALL

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age \>/= 18 years~* New Diagnosis of Bcr-Abl positive ALL or Bcr-Abl negative ALL~* Receiving induction chemotherapy with the standard Princess Margaret Hospital modified DFCI protocol~* Will have a functioning central venous access catheter in-situ~* Agreeing to participate in the study and sign the informed consent form~Exclusion Criteria:~* Concomitant use of other agents that inhibit hepatic cytochrome CYP3A4, as these drugs may alter vincristine and imatinib levels~* Elevated liver function tests: bilirubin \>1.5xULN or AST/ALT \>2.5xULN, or documented history of chronic liver disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bcr-Abl positive ALL (Type: None): None
- Bcr-Abl negative ALL (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).